JP2020073561A5 - - Google Patents

Download PDF

Info

Publication number
JP2020073561A5
JP2020073561A5 JP2020001139A JP2020001139A JP2020073561A5 JP 2020073561 A5 JP2020073561 A5 JP 2020073561A5 JP 2020001139 A JP2020001139 A JP 2020001139A JP 2020001139 A JP2020001139 A JP 2020001139A JP 2020073561 A5 JP2020073561 A5 JP 2020073561A5
Authority
JP
Japan
Prior art keywords
amino
oxo
dihydro
phenoxyphenyl
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020001139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020073561A (ja
JP6985433B2 (ja
Filing date
Publication date
Priority claimed from JP2017562758A external-priority patent/JP6646072B2/ja
Application filed filed Critical
Publication of JP2020073561A publication Critical patent/JP2020073561A/ja
Publication of JP2020073561A5 publication Critical patent/JP2020073561A5/ja
Application granted granted Critical
Publication of JP6985433B2 publication Critical patent/JP6985433B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020001139A 2015-06-03 2020-01-08 チロシンキナーゼ阻害剤 Active JP6985433B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562170547P 2015-06-03 2015-06-03
US62/170,547 2015-06-03
US201562271689P 2015-12-28 2015-12-28
US62/271,689 2015-12-28
JP2017562758A JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017562758A Division JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2020073561A JP2020073561A (ja) 2020-05-14
JP2020073561A5 true JP2020073561A5 (enExample) 2020-07-09
JP6985433B2 JP6985433B2 (ja) 2021-12-22

Family

ID=56118090

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017562758A Active JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤
JP2020001139A Active JP6985433B2 (ja) 2015-06-03 2020-01-08 チロシンキナーゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017562758A Active JP6646072B2 (ja) 2015-06-03 2016-06-02 チロシンキナーゼ阻害剤

Country Status (33)

Country Link
US (5) US20180162861A1 (enExample)
EP (3) EP3912979A1 (enExample)
JP (2) JP6646072B2 (enExample)
KR (3) KR102552653B1 (enExample)
CN (2) CN113149983B (enExample)
AU (2) AU2016270973B2 (enExample)
CA (1) CA2987335A1 (enExample)
CL (2) CL2017003073A1 (enExample)
CO (1) CO2017012947A2 (enExample)
CR (1) CR20170593A (enExample)
DK (1) DK3303334T3 (enExample)
DO (1) DOP2017000279A (enExample)
EA (1) EA039006B1 (enExample)
ES (1) ES2878030T3 (enExample)
HK (1) HK1252378A1 (enExample)
HR (1) HRP20211249T1 (enExample)
HU (1) HUE055419T2 (enExample)
IL (2) IL255946A (enExample)
LT (1) LT3303334T (enExample)
MX (2) MX383213B (enExample)
MY (1) MY190548A (enExample)
PE (1) PE20180521A1 (enExample)
PH (2) PH12021551681A1 (enExample)
PL (1) PL3303334T3 (enExample)
PT (1) PT3303334T (enExample)
RS (1) RS62290B1 (enExample)
SG (1) SG10201912443XA (enExample)
SI (1) SI3303334T1 (enExample)
TN (1) TN2017000501A1 (enExample)
TW (2) TWI732765B (enExample)
UA (1) UA124090C2 (enExample)
WO (1) WO2016196840A1 (enExample)
ZA (2) ZA201708667B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159635B (zh) 2012-02-27 2018-09-25 奥雷制药有限公司 用于耳蜗内递送治疗剂以治疗耳部病症的固体药物植入物
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
EP3075681B1 (en) 2013-11-29 2021-06-02 Daizo Corporation Content-accommodating container, content-accommodating product using same, discharging product, and discharging device
MX372673B (es) 2014-02-21 2020-03-25 Principia Biopharma Inc Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
MA41197B1 (fr) 2014-12-18 2021-01-29 Principia Biopharma Inc Traitement de le pemphigus
CN113149983B (zh) * 2015-06-03 2024-03-29 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
EP3414234B1 (en) * 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP3487857B1 (en) * 2016-07-25 2021-09-01 Nerviano Medical Sciences S.r.l. Purine and 3-deazapurine analogues as choline kinase inhibitors
WO2018156901A1 (en) * 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
JP7331843B2 (ja) * 2018-04-27 2023-08-23 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
KR102612513B1 (ko) 2018-07-31 2023-12-12 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
FI3808747T3 (fi) * 2018-09-13 2025-02-07 Kissei Pharmaceutical Imidatsopyridinoniyhdiste
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN115209899A (zh) 2019-10-14 2022-10-18 普林斯匹亚生物制药公司 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法
IL294560A (en) * 2020-01-20 2022-09-01 Genzyme Corp Medicinal tyrosine kinase inhibitors for relapsing multiple sclerosis
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20220130184A (ko) 2020-01-22 2022-09-26 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)-1H-피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 결정질 형태
CN115397427A (zh) * 2020-03-30 2022-11-25 Igia制药有限公司 酪氨酸激酶抑制剂的儿科制剂
WO2022033460A1 (zh) * 2020-08-10 2022-02-17 江苏恒瑞医药股份有限公司 Btk抑制剂治疗疾病的用途
KR20230051227A (ko) 2020-08-14 2023-04-17 노파르티스 아게 헤테로아릴 치환된 스피로피페리디닐 유도체 및 이의 제약 용도
EP4237423B1 (en) 2020-11-02 2024-12-11 Boehringer Ingelheim International GmbH Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
WO2022121670A1 (zh) 2020-12-10 2022-06-16 苏州科睿思制药有限公司 Tolebrutinib的晶型及其制备方法和用途
CA3206176A1 (en) * 2020-12-23 2022-06-30 Catherine ARABEYRE 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
CN116710452A (zh) * 2020-12-23 2023-09-05 建新公司 4-氨基-3-(4-苯氧基苯基)-1,3-二氢-2h-咪唑并[4,5-c]吡啶-2-酮衍生物及其盐类
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
US20240217973A1 (en) * 2021-04-16 2024-07-04 Medshine Discovery Inc. Imidazopyridine compounds and use thereof
EP4328226A4 (en) 2021-04-23 2025-08-27 Hangzhou Solipharma Co Ltd CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF
WO2022242740A1 (zh) * 2021-05-21 2022-11-24 杭州领业医药科技有限公司 Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
AU2022290946A1 (en) 2021-06-11 2024-01-25 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
WO2023280132A1 (zh) * 2021-07-06 2023-01-12 苏州晶云药物科技股份有限公司 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法
JP2024533724A (ja) * 2021-09-24 2024-09-12 ドナルドソン，チャドウィック 粘膜を通して薬剤を送達するための乾燥粉末発泡性製剤
KR20240125005A (ko) 2021-12-21 2024-08-19 프린시피아 바이오파마, 인코퍼레이티드 (r)-1-(1-아크릴로일피페리딘-3-일)-4-아미노-3-(4-페녹시페닐)-1h-이미다조[4,5-c]피리딘-2(3h)-온의결정질 형태 및 이의 염
WO2023172663A1 (en) * 2022-03-09 2023-09-14 Teva Pharmaceuticals International Gmbh Solid state forms of tolebrutinib and of tolebrutinib salts
US20230399313A1 (en) * 2022-06-10 2023-12-14 Advenchen Pharmaceuticals, LLC Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
CA3259195A1 (en) * 2022-06-14 2023-12-21 Principia Biopharma Inc. TOLEBRUTINIB MANUFACTURING PROCESSES
AR129672A1 (es) * 2022-06-22 2024-09-18 Genzyme Corp Métodos de fabricación de inhibidores de btk modificados
EP4547249A1 (en) 2022-06-30 2025-05-07 Principia Biopharma Inc. Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
JP2025534632A (ja) 2022-10-11 2025-10-17 プリンシピア バイオファーマ インコーポレイテッド 多発性硬化症治療のためのチロシンキナーゼ阻害剤
CN118891260B (zh) * 2022-11-07 2025-07-25 天津瑞程健达医药科技有限公司 氘代的氨基吡啶衍生物以及包含该化合物的药物组合物
AU2023408758A1 (en) 2022-12-20 2025-07-31 Principia Biopharma Inc. Drug formulations of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4- phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one
AU2024214470A1 (en) 2023-02-01 2025-09-11 Principia Biopharma Inc. Methods of diagnosing and treating multiple sclerosis by detecting a biomarker in the cerebrospinal fluid
WO2025188862A1 (en) 2024-03-06 2025-09-12 Principia Biopharma Inc. Methods of making tolebrutinib

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
US20060045822A1 (en) 2004-09-01 2006-03-02 Board Of Regents, The University Of Texas System Plasma polymerization for encapsulating particles
JP4769810B2 (ja) * 2004-09-14 2011-09-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド イミダゾキノリン化合物
EP1846405A2 (en) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
ES2673973T3 (es) * 2006-09-22 2018-06-26 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
IN2012DN02534A (enExample) 2009-09-16 2015-08-28 Avila Therapeutics Inc
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP3590938B1 (en) * 2010-05-31 2023-05-24 ONO Pharmaceutical Co., Ltd. Purinone derivative as btk kinase inhibitor
HUE048834T2 (hu) * 2011-05-17 2020-08-28 Univ California Kináz inhibitorok
HUE033019T2 (en) * 2011-05-17 2017-11-28 Principia Biopharma Inc Tyrosine kinase inhibitors
WO2012158785A1 (en) * 2011-05-17 2012-11-22 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
HRP20161377T1 (hr) * 2011-11-29 2017-02-10 Ono Pharmaceutical Co., Ltd. Purinonski derivati klorovodika
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
CA2874461C (en) 2012-06-18 2021-10-12 Principia Biopharma Inc. Formulations containing reversible covalent compounds
PT2872491T (pt) 2012-07-11 2021-08-05 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
SI2892900T1 (en) * 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
US20140142099A1 (en) * 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN113149983B (zh) * 2015-06-03 2024-03-29 普林斯匹亚生物制药公司 酪氨酸激酶抑制剂
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2020073561A5 (enExample)
JP6776399B2 (ja) ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用
US7642263B2 (en) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP6218260B2 (ja) Ｊａｋ阻害剤としてのアミノピリミジニル化合物
US8329711B2 (en) Pyridone-substituted-dihydropyrazolopyrimidinone derivative
US7745475B2 (en) Heteroaryl benzamide derivatives as GLK activators
US20100160286A1 (en) Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
JP2019504821A5 (enExample)
JP2009541268A5 (enExample)
US20190345138A1 (en) Heterocyclic amides as kinase inhibitors
CN114269432A (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
US20110053910A1 (en) 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
JP2015500862A5 (enExample)
TW201725202A (zh) 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途
CA2677572A1 (en) 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors
CN107257686A (zh) 天疱疮的治疗
JP2017052805A5 (enExample)
HUE026041T2 (en) Pyrrolo-triazinone derivatives as P13K inhibitors
JP2009513575A5 (enExample)
US7655652B2 (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
RU2014152257A (ru) Гетероциклильные пиримидиновые аналоги в качестве ингибиторов tyk2
JP2019523233A5 (enExample)
JP2009525978A5 (enExample)
JP6983945B2 (ja) 自己免疫性疾患の処置
JP2004508366A5 (enExample)